Generated by DeepSeek V3.2| naproxen | |
|---|---|
| IUPAC name | (S)-2-(6-Methoxynaphthalen-2-yl)propanoic acid |
| Tradename | Aleve, Naprosyn, others |
| Drugs.com | monograph, naproxen |
| MedlinePlus | a681029 |
| Routes of administration | By mouth, rectal |
| Bioavailability | 95% |
| Protein bound | >99% |
| Metabolism | Liver (CYP2C9 and CYP1A2) |
| Elimination half-life | 12–17 hours |
| Excretion | Urine (95%) |
| CAS number | 22204-53-1 |
| PubChem | 156391 |
| ChemSpiderID | 137720 |
| UNII | 57Y76R9ATQ |
| ChEBI | 7476 |
| ChEMBL | 154 |
| ATC prefix | M01 |
| ATC suffix | AE02 |
| License US | Naproxen |
| License data US | Rx-only (suspension), OTC (tablets) |
| Legal US | OTC |
| Legal EU | Rx-only |
| Legal status | Rx-only, OTC |
naproxen is a nonsteroidal anti-inflammatory drug used to treat pain, fever, and inflammation. It is available by prescription and over-the-counter in many countries under brand names such as Aleve and Naprosyn. The medication is commonly used for conditions like osteoarthritis, rheumatoid arthritis, and dysmenorrhea.
It is prescribed for the management of pain and inflammation associated with various conditions, including ankylosing spondylitis, tendinitis, and bursitis. Clinicians often recommend it for acute gout attacks and to reduce fever. Its efficacy in treating migraine headaches has been established in clinical studies conducted by institutions like the American Headache Society. Compared to other NSAIDs like ibuprofen, it has a longer duration of action, allowing for less frequent dosing.
Common side effects include dyspepsia, headache, and dizziness. Serious risks involve gastrointestinal bleeding, which can be exacerbated when taken with other medications like warfarin. The U.S. Food and Drug Administration has issued warnings about increased risk of myocardial infarction and stroke, similar to other NSAIDs. Rare but severe reactions include Stevens–Johnson syndrome and toxic epidermal necrolysis, as documented in reports from the World Health Organization.
It works by inhibiting the cyclooxygenase enzymes, COX-1 and COX-2, which reduces the synthesis of prostaglandins. This action occurs primarily in the peripheral nervous system and at sites of inflammation. Its metabolism is mediated by hepatic enzymes, specifically CYP2C9 and CYP1A2, and it is highly bound to plasma proteins. The drug's long half-life contributes to its sustained therapeutic effect, a property studied extensively at the National Institutes of Health.
It was first approved for medical use in the United States in 1976 and is on the World Health Organization's List of Essential Medicines. The over-the-counter marketing of brands like Aleve is managed by Bayer in many regions. Patent disputes involving the drug have been litigated in courts including the Supreme Court of the United States. Its use in professional sports, under regulations from bodies like WADA, is monitored due to potential performance-enhancing masking effects.
Chemically, it is a propionic acid derivative with the molecular formula C₁₄H₁₄O₃. The active enantiomer is the S-isomer, while the racemic mixture was originally marketed as Naprosyn. Its synthesis typically involves a Friedel–Crafts acylation of 2-methoxynaphthalene. The crystalline structure and properties have been analyzed using techniques like X-ray crystallography at facilities such as the University of Cambridge.
Category:Drugs